PeptiDream Inc (PPTDF)
13.11
0.00 (0.00%)
USD |
OTCM |
May 03, 16:00
PeptiDream SG&A Expense (Quarterly): 13.94M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 13.94M |
September 30, 2023 | 12.24M |
June 30, 2023 | 12.61M |
March 31, 2023 | 12.86M |
December 31, 2022 | 15.35M |
September 30, 2022 | 11.89M |
Date | Value |
---|---|
June 30, 2022 | 13.26M |
March 31, 2022 | 5.986M |
December 31, 2021 | 2.718M |
September 30, 2021 | 2.447M |
June 30, 2021 | 15.80M |
March 31, 2021 | 5.423M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
2.447M
Minimum
Sep 2021
15.80M
Maximum
Jun 2021
10.38M
Average
12.43M
Median
SG&A Expense (Quarterly) Benchmarks
Takeda Pharmaceutical Co Ltd | 1.812B |
Nxera Pharma Co Ltd | 26.77M |
Stemcell Holdings Inc | 0.8358M |
Healios KK | 2.133M |
AnGes Inc | 9.706M |